

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Flomerfelt *et al.*

Application No. 10/579,879

Filed: May 17, 2006

Confirmation No. 4862

SUBMITTED VIA EFS

For: SPATIAL FOR ALTERING CELL
PROLIFERATION

Examiner: Boesen

Art Unit: 1648

Attorney Reference No. 4239-64851-02

SUBMITTED VIA ELECTRONIC FILING SYSTEM
COMMISSIONER FOR PATENTS

**REQUEST FOR REPUBLICATION OF PATENT APPLICATION PUBLICATION
UNDER 37 C.F.R. §1.221(b)**

Applicants hereby request republication of this application, which request is being made within two months of the October 25, 2007, publication of this application; that is, no later than **December 25, 2007**. It is believed that this request is complete and proper.

At least the material mistakes listed below appear in the application publication, which mistakes include one or more of error(s) in the claims, error(s) in the (effective) filing date of the application, and/or serious errors in the written description that supports the published claims. The listed errors are apparent from the Office records.

In the Specification:

The application publication did not include the benefit claim to prior-filed nonprovisional application(s), which specific reference was timely submitted by preliminary amendment on May 17, 2006 (accompanying the filing of the application). The following should appear beginning on page 1, at line 2:

--REFERENCE TO RELATED APPLICATION

This is a §371 U.S. National Stage of International Application No. PCT/US2003/036874, filed November 18, 2003, which application is incorporated herein in its entirety. --

On page 3, at lines 4-6 of [0021]: “cells were reacted with 3H-Indolium, 2-[3(1,3-dihydro-3,3-dimethyl-1-octadecyl-2H-indol-2-ylidene)-propenyl]-3,3-dimethyl-octadecyl-, perchlorate”

should read – cells were reacted with 3H-Indolium, 2-[3-(1,3-dihydro-3,3-dimethyl-1-octadecyl-2H-indol-2-ylidene)-1-propenyl]-3,3-dimethyl-1-octadecyl-, perchlorate – .

On page 4, at line 20 of [0042]: “transcobalamin-H-deficiency” should read – transcobalamin II deficiency – .

On page 7, at line 17 of [0099]: “(N=mitotic).” should read – (M=mitotic). –.

On page 22, at line 7 of [0231]: “foriculitis” should read – folliculitis –.

On page 29, at line 10 of [0302]: “(n=2)” should read – (n=2) –.

On page 33, at lines 4-6 of [0369]: “3H-Indolium, 2-[3-(1,3-dihydro-3,3-dimethyl-1-octadecyl-2H-indol-2-ylidene) 1-propenyl]-3,3-dimethyl-1-octadecyl-,”

should read – 3H-Indolium, 2-[3-(1,3-dihydro-3,3-dimethyl-1-octadecyl-2H-indol-2-ylidene)-1-propenyl]-3,3-dimethyl-1-octadecyl-, – .

On page 34, at line 15 of [0379]: “of 0.11 mM.” should read – of 0.1 mM. – .

On page 36, at line 3 of [0399]: “incubated for 14 hours” should read – incubated for 1-4 hours – .

In the Claims:

On page 51, in line 7 of claim 48, “thrombocytopena” should read – thrombocytopenia –.

Conclusion

Applicants believe this request is complete as submitted. However, if the Office determines that additional information is required, please contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630